Serving science company Thermo Fisher Scientific revealed on Tuesday the launch of the new AcroMetrix Coronavirus 2019 (COVID-19) RNA Control product to monitor and validate COVID-19 molecular diagnostic tests.
The company has designed and developed this control as a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests at two different concentrations: a low positive control and an ultra-low positive control under FDA guidelines.
AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is prepared by formulating synthetic RNA transcripts with highly unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into proprietary buffer. The kit contains two vials of SARS-CoV-2 specific RNA that will result low positive and ultra-low positive in used Polymerase Chain Reaction (PCR) based Coronavirus 2019 nucleic acid testing methods.
Additionally, the company's online resource has up-to-date information about its response to the COVID-19 pandemic, including availability of diagnostic test kits. The COVID-19 RNA Control is available as a Research Use Only (RUO) product and is not intended for clinical use.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress